Search Results - "Mettinger, K"

A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer by Baka, S., Ranson, M., Lorigan, P., Danson, S., Linton, K., Hoogendam, I., Mettinger, K., Thatcher, N.

“…Rubitecan (RFS2000, 9 nitrocamptothecin,) is a new oral topoisomerase I inhibitor. We report a phase II, single-arm, open-label study of RFS2000 as first line…”
Get full text

The protective role of the immunomodulator AS101 against chemotherapy‐induced alopecia studies on human and animal models by Sredni, Benjamin, Xu, Ren‐He, Albeck, Michael, Gafter, Uzi, Gal, Rivka, Shani, Adi, Tichler, Thomas, Shapira, Jeremy, Bruderman, Israel, Catane, Rafael, Kaufman, Bella, Whisnant, John K., Mettinger, Karl L., Kalechman, Yona

“…The immunomodulator AS101 has been demonstrated to exhibit radioprotective and chemoprotective effects in mice. Following phase‐I studies, preliminary results…”
Get full text

Fibromuscular dysplasia and the brain. II. Current concept of the disease by Mettinger, K L

“…Eleven hundred cases from the literature of fibromuscular dysplasia (FMD) are reviewed including 300 cases with aortocranial lesions. The male-female ratio is…”
Get full text

1235 A phase-I study of the combination of intravenous reovirus (REOLYSIN ®) and gemcitabine in patients with advanced cancer by Lolkema, M.P, Harrington, K, Evans, J, Arkenau, H.T, Roxburgh, P, Morrison, R, Roulstone, V, Coffey, M, Mettinger, K, de Bono, J

Get full text

Fibromuscular dysplasia and the brain. I. Observations on angiographic, clinical and genetic characteristics by Mettinger, K L, Ericson, K

“…The angiographic, clinical, and genetic characteristics of fibromuscular dysplasia (FMD) are reviewed in 37 patients (mean age 48 years) selected from a pool…”
Get full text

Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors by de Jonge, M J A, Droz, J P, Paz-Ares, L, van Oosterom, A T, de Wit, R, Chollet, P, Baron, B, Lacombe, D, Mettinger, K, Fumoleau, P

“…To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract…”
Get full text

The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma by Kalechman, Y, Shani, A, Dovrat, S, Whisnant, JK, Mettinger, K, Albeck, M, Sredni, B

“…The immunomodulator ammonium trichloro(dioxyethylene-0-0')tellurate (AS101) has been shown to possess antitumoral properties in several murine models. In the…”
Get full text

Effects of Alzene and tacrine on water maze reference and working memory function in medial septal-lesioned rats by Riekkinen, P., Mettinger, K.L., Karukin, M., Riekkinen, M.

“…The present study investigated the effects of repeated daily administration of a mixture containing free fatty acids (α-linolenic/linoleic acid in a 1:4 ratio…”
Get full text

Thrombolytic intervention and its effect on mortality in acute myocardium infarction by Mettinger, K L

Get more information

Epidemiology of acute cerebrovascular disease before the age of 55 in the Stockholm County 1973-77: I. Incidence and mortality rates by Mettinger, K L, Söderström, C E, Allander, E

“…The incidence and mortality rates of cerebrovascular disease (CVD) before age 55 were estimated for the Stockholm county between 1973 and 1977 using community…”
Get full text

Randomized trial of cervene, a κ receptor-selective opioid antagonist, in acute ischemic stroke by Clark, W.M., Coull, B.M., Karukin, M., Hendin, B., Kelley, R., Rosing, H., Zachariah, S., Winograd, M., Raps, E., Walshe, T., Singer, S., Mettinger, K.L.

“…The purpose of this randomized trial was to confirm drug safety and to obtain preliminary efficacy data on Cervene (nalmefene), an opioid antagonist with…”
Get full text

A study of hemostasis in ischemic cerebrovascular disease. I. Abnormalities in factor VIII and antithrombin by Mettinger, K L

“…A sample of in all 119 young adults below the age of 55, with ischemic cerebrovascular disease (TIA and minor stroke), was investigated later than three months…”
Get more information

Stroke before 55 years of age at Karolinska Hospital 1973-77. A study of 399 well-defined cases. Risk indicators and etiological considerations by Mettinger, K L, Söderström, C E, Neiman, J

“…The etiological characteristics of cerebrovascular disease (CVD) before the age of 55 are reviewed in 399 patients admitted to the Department of Neurology,…”
Get more information

Multicenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcoma by Tulpule, Anil, Groopman, Jerome, Saville, M. Wayne, Harrington, William, Friedman‐Kien, Alvin, Espina, Byron M., Garces, Carlos, Mantelle, Lily, Mettinger, Karl, Scadden, David T., Gill, Parkash S.

“…BACKGROUND Treatment options are limited for patients with advanced acquired immunodeficieny syndrome (AIDS)‐related Kaposi sarcoma (AIDS‐KS) whose disease has…”
Get full text

A phase I/II study of oncolytic reovirus plus carboplatin/paclitaxel in patients with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN) by Karapanagiotou, E. M., Chester, J. D., Pandha, H. S., Gill, G. M., Coffey, M. C., Mettinger, K., Harrington, K. J.

“…Abstract only…”
Get full text

Dose escalation and pharmacodynamic study of intravenous adminstration of Reolysin, a live replication competent RNA virus in patients with advanced solid tumors by Ghalib, M. H., Desai, K. K., Gollamudi, R., Chaudhary, I., Einstein, M., Coffey, M., Mettinger, K., Mani, S., Goel, S.

“…Abstract only 3583 Background: Reolysin is reovirus serotype 3 - Dearing strain, a double-stranded replication- competent RNA non-enveloped icosahedral virus…”
Get full text

Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers by Saunders, M., Anthoney, A., Coffey, M., Mettinger, K., Thompson, B., Melcher, A., Nutting, C. M., Harrington, K.

“…Abstract only e14514 Background: Reolysin, a wild type reovirus serotype 3 Dearing strain, replicates preferentially in Ras-activated cancer cells. In vitro…”
Get full text

A study of hemostasis in ischemic cerebrovascular disease: IV. A five year follow-up of some blood coagulation parameters also including fibrinopeptide A, factor XII and prekallikrein by Mettinger, K L

“…Twenty-seven young adults (mean age 46) with ischemic cerebrovascular disease (ICD) were reinvestigated about 5 years after discharge and compared to 67…”
Get more information

A study of hemostasis in ischemic cerebrovascular disease. V. A multivariate evaluation of risk indicators and predictors. Early results of a longitudinal study by Mettinger, K L

“…The study includes 119 patients with minor ischemic cerebrovascular lesions before the age of 55 during 1976-78. Atherosclerotic signs were found in 65% at…”
Get more information

A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung by Mita, A. C., Sankhala, K., Sarantopoulos, J., Carmona, J., Okuno, S., Goel, S., Chugh, R., Coffey, M. C., Mettinger, K., Mita, M. M.

“…Abstract only 10524 Background: Reolysin is a Dearing strain, naturally occurring, ubiquitous human reovirus. The PKR (double stranded RNA-activated protein…”
Get full text